BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) P/E ratio
As of 16 October 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a P/E ratio of 62.6×. Over the past ten years it has ranged from 0.0× (September 2025) to 651× (November 2025); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 116× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 48.3× | (24.37%) |
| Mar 2026 | 63.9× | (45.13%) |
| Dec 2025 | 116× | (80.18%) |
| Sep 2025 | 587× | — |
| 39 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| INCY Incyte Corporation compare | 13.9× |
| GMAB Genmab A/S Sponsored ADR compare | 29.1× |
| ARGX argenex SE compare | 29.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 39.5× |
| RPRX Royalty Pharma PLC compare | 42.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 62.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)